A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of a new allergy medication

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bausch & Lomb Incorporated
• Treatments: Ketotifen; Vasoconstrictor Agents

Criteria

Inclusion Criteria:

• Be at least 6 years of age, of any race, or either gender.

• Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.

• Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.

• Positive bilateral CAC reaction at Visit 1 & 2.

Exclusion Criteria:

• Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.

• Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters

• Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit